Table 1 Description of included studies.

From: Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis

Study	Setting of treatment	Initial therapy regimen	Consolidation/maintenance regimen	Patient No.
Stadtmauer et al.¹⁹^a	Consolidation	Heterogeneous regimens, ~80% pts received bor	Bor 1.3 mg/m² i.v. days 1, 4, 8, and 11 + len 15 mg/d days 1 to 14 + dex 40 mg/d days 1, 8, and 15; 21-day cycle, 4 cycles	254
Stadtmauer et al.¹⁹^a	Consolidation	Heterogeneous regimens, ~80% pts received bor	No consolidation	257
Horvath et al.²⁰	Consolidation	Bor s.c. + cyclophosphamide + dex	Bor 1.3 mg/m² s.c. every 2 weeks, 32 weeks + thal 100 mg/d, 1 year + prednisolone 50 mg on alternate days	103
Horvath et al.²⁰	Consolidation	Bor s.c. + cyclophosphamide + dex	Thal 100 mg/d, up to 1 year + prednisolone 50 mg on alternate days	100
Einsele et al.²¹^b	Consolidation	Heterogeneous regimens, 50% pts received bor	Bor 1.6 mg/m² i.v. days 1, 8, 15, and 22; 35-day cycle, 4 cycles	177
Einsele et al.²¹^b	Consolidation	Heterogeneous regimens, 50% pts received bor	Observation	180
Sezer et al.²²^c	Consolidation	Heterogeneous regimens, 68% pts received bor	Bor 1.6 mg/m² i.v. days 1, 8, 15, and 22; 35-day cycle, 4 cycles	51
Sezer et al.²²^c	Consolidation	Heterogeneous regimens, 68% pts received bor	Observation	53
Mellqvist et al.²⁵^b	Consolidation	Heterogeneous regimens, no pts received bor	Bor 1.3 mg/m² i.v. days 1, 4, 8, and 11, 21-day cycle, 2 cycles, then days 1, 8, and 15, 28-day cycle, 4 cycles	187
Mellqvist et al.²⁵^b	Consolidation	Heterogeneous regimens, no pts received bor	Observation	183
Cavo et al.²⁷	Consolidation	Bor + thal + dex	Bor 1.3 mg/m² i.v. days 1, 8, 15, and 22 + thal 100 mg/d + dex 40 mg/d days 1, 2, 8, 9, 15, 16, 22, and 23; 35-day cycle, 2 cycles	160
Cavo et al.²⁷	Consolidation	Thal + dex	Thal 100 mg/d + dex 40 mg/d days 1, 2, 8, 9, 15, 16, 22, and 23; 35-day cycle, 2 cycles	161
Rosinol et al.²³^b	Maintenance	Heterogeneous regimens, 34% pts received bor	Bor 1.3 mg/m² i.v. days 1, 4, 8, and 11 every 3 months + thal 100 mg/d, up to 3 years	91
			Thal 100 mg/d, up to 3 years	88
			Alfa2-IFN starting at 1.5 MU (could be increased to 3 MU) s.c. 3 times per week, up to 3 years	92
Palumbo et al.²⁴^d	Maintenance	Bor + mel + prednisone + thal	Bor 1.3 mg/m² i.v. every 15 days + thal 50 mg/d, up to 2 years	254
Palumbo et al.²⁴^d	Maintenance	Bor + mel + prednisone	Observation	257
Sonneveld et al.^26,35,36^b	Maintenance	Bor + doxorubicin + dex	Bor 1.3 mg/m² i.v. every 2 weeks, up to 2 years	229
Sonneveld et al.^26,35,36^b	Maintenance	Vincristine + doxorubicin + dex	Thal 50 mg/d, up to 2 years	270

Alfa2-IFN interferon alfa-2b, ASCT autologous stem cell transplantation, bor bortezomib, dex dexamethasone, i.v. intravenous, len lenalidomide, MU million units, pts patients, s.c. subcutaneous, thal thalidomide.
^aOnly the two relevant arms were shown in the table.
^bThe authors provided additional updated data (personal communication) that were used in this meta-analysis.
^cOpen-label phase II trial; all others were open-label phase III trials.
^dNo ASCT; all others included ASCT.

Back to article page

Table 1 Description of included studies.

Search

Quick links